| Authors: |
Tang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sethunath V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Metaferia NY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Nogueira MF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gallant DS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Garner ER; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lairson LA; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Penney CM; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gelbard MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Alaiwi SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Hwang JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Strathdee CA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., AbuHammad S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zhang X; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA., Doench JG; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA., Takeda DY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA., Choi PS; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: peter.choi@pennmedicine.upenn.edu., Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA. Electronic address: srinivas.viswanathan@dfci.harvard.edu. |
